Industry News
Biotechnology Industry News
Protego Biopharma will use the…
Protego Biopharma will use the funding to run pivotal studies of its amyloid light-chain amyloidosis prospect PROT-001.
AbbVie is opening up submissions…
AbbVie is opening up submissions for an award that will provide one Canadian biotech free access to lab space and executive insights from the Big Pharma.
Amid a groundswell of questions…
Amid a groundswell of questions and pushback over the FDA's Commissioner's National Priority Voucher program, two lawmakers are seeking to gain more clarity.
Novo Nordisk is hitting the gas on…
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity prospect.
A drug safety group has delivered…
A drug safety group has delivered a positive analysis for a Sarepta-licensed RNA medicine, with the same study also hitting an enrollment target. The latter development has triggered a $200 milestone payment due to Arrowhead
Swedish biotech Sprint Bioscience…
Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus the chance to net up to $400 million in biobucks.
VC Versant Ventures is unveiling…
VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen.
Johnson & Johnson’s attempt…
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to significantly slow clinical decline,
Bayer’s oral FXIa inhibitor…
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past two years.
Hundreds of industry leaders have…
Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were
The FDA is hiring more than 1,000…
The FDA is hiring more than 1,000 new employees and rolling out a pilot communication program in an effort to speed up the review of new drugs.
No matter who Fierce could pull…
No matter who Fierce could pull aside for a quick coffee at the conference, the general view was of a renewed sense of cautious optimism.
Nurix Therapeutics is trimming its…
Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset.
Contineum Therapeutics’ M1…
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis.
Gilead’s general counsel and EVP…
Gilead’s general counsel and EVP of corporate affairs Deborah Telman will hang up the gloves by Dec. 5, the company announced in a brief filing Nov. 15. Gilead didn’t offer any explanation for Telman’s departure,
Moderna, an mRNA specialist known…
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases.
Pfizer has released the full data…
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to a control vaccine.
Genetic medicines outfit Ensoma is…
Genetic medicines outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research functions.
Facing skepticism from analysts…
Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics is laying off almost half its workforce to conserve its remaining cash.
Novartis may have signed off on…
Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees it—it’s never about the price tag.